产品说明书
Milnacipran HCl
 |
同义名 : | 米那普仑盐酸盐 ;Milnacipran (hydrochloride);F 2207;Milnacipran hydrochloride |
| CAS号 : | 101152-94-7 | |
| 货号 : | A139696 | |
| 分子式 : | C15H23ClN2O | |
| 纯度 : | 98% | |
| 分子量 : | 282.809 | |
| MDL号 : | MFCD00901293 | |
| 存储条件： |
粉末 Inert atmosphere,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(176.8 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 100 mg/mL(353.6 mM) |
|
| 动物实验配方： |
PO 0.5% CMC-Na 50 mg/mL clear |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Major depressive disorder (MDD) is a debilitating disease that is characterized by depressed mood, diminished interests, impaired cognitive function and vegetative symptoms, such as disturbed sleep or appetite[3]. (1S-cis)-Milnacipran Hydrochloride is the latest antidepressants approved for the treatment of MDD. It acts through an increased serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin (5-HT). In addition to the SSRI activity, (1S-cis)-Milnacipran Hydrochloride is also a norepinephrine reuptake inhibitor[4]. In seven randomised, double-blind clinical trials, levomilnacipran is generally more effective than placebo for the treatment of MDD in the short-term. Preliminary evidence suggests that levomilnacipran extended release may be effective in improving not only depressive symptoms but also symptoms related to functioning (social life, work, and family life)[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00605917 | - | Completed | - | - | |
| NCT00605917 | - | Completed | - | - | |
| NCT00605865 | - | Completed | - | - | |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.54mL 0.71mL 0.35mL |
17.68mL 3.54mL 1.77mL |
35.36mL 7.07mL 3.54mL |
| 参考文献 |
|---|
|
[3]Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nat Rev Dis Primers. 2016;2:16065 |